North Carolina Headlines

DelveInsight’s, “Chronic Kidney Disease Pipeline Insight 2026” report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in the Chronic Kidney Disease pipeline landscape. It covers the Chronic Kidney Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chronic Kidney Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Chronic Kidney Disease Research @ https://www.delveinsight.com/sample-request/chronic-kidney-disease-ckd-pipeline-insight

Key Takeaways from the Chronic Kidney Disease Pipeline Report

• On June 11, 2026- Vifor Fresenius Medical Care Renal Pharma initiated a study is to evaluate the safety and tolerability, as assessed by incidence of AEs, of 0.5 μg/kg IV difelikefalin in adolescent participants on HD (3 times weekly) with moderate-to-severe pruritus over 12 weeks. Additionally, difelikefalin plasma concentrations (Cmax and Ctrough) after multiple administrations will be evaluated at a few selected time points and the efficacy of difelikefalin in improving itching and health-related QoL will be investigated as exploratory.
• On June 11, 2026- Boehringer Ingelheim conducted a study is open to children aged 2 to 17 with chronic kidney disease (CKD). The purpose of this study is to find out if a medicine called empagliflozin helps children and adolescents with CKD. Other goals of the study are to find out how empagliflozin is tolerated and handled by the body in children and adolescents with CKD.
• On June 04, 2026- Novartis Pharmaceuticals initiated a ALIGN Study is a phase 3, double-blind, placebo-controlled study to compare the efficacy and safety of atrasentan to placebo in patients with IgA nephropathy (IgAN) at risk of progressive loss of renal function.
• On June 03, 2026- Mineralys Therapeutics Inc. announced a phase 2 study with a two-period, two-sequence (2×2) design evaluating the efficacy and safety of 25 mg QD lorundrostat (an aldosterone synthase inhibitor [ASI]) in addition to a SGLT2i for the treatment of hypertension in subjects with CKD and albuminuria while receiving stable treatment with an Angiotensin-converting enzyme inhibitor (ACEi) or an Angiotensin receptor blocker (ARB). Subjects will be at least 18 years old with hypertension, and mild to severe CKD with albuminuria at the Screening Visit.
• On May 01, 2026- Medical College of Wisconsin initiated a study aimed to analyze the immunogenicity of nanovalent human papillomavirus vaccination (GARDASIL 9) in post-solid-organ transplant patients. The study duration is anticipated to be 36 months. The expected duration of subject participation is 24 months. Immunocompromised populations are at greater risk of HPV infection. Quadrivalent HPV vaccination has been performed and lower titers of antibodies have been compared to published date in non-immunocompromised population (controls). The HPV9 vaccination titers have not been measured in the immunocompromised population to date.
• On May 01, 2026- Vifor Fresenius Medical Care Renal Pharma conducted a study is to evaluate the safety and tolerability, as assessed by incidence of AEs, of 0.5 μg/kg IV difelikefalin in adolescent participants on HD (3 times weekly) with moderate-to-severe pruritus over 12 weeks. Additionally, difelikefalin plasma concentrations (Cmax and Ctrough) after multiple administrations will be evaluated at a few selected time points and the efficacy of difelikefalin in improving itching and health-related QoL will be investigated as exploratory.
• DelveInsight’s Chronic Kidney Disease pipeline report depicts a robust space with 75+ active players working to develop 80+ pipeline therapies for Chronic Kidney Disease treatment.
• The leading Chronic Kidney Disease Companies such as AstraZeneca, Eli Lilly and Company, Shandong Suncadia Medicine, Boehringer Ingelheim, AdAlta, Alebund Pharmaceuticals, SCOHIA PHARMA, DiaMedica Therapeutics, Roche, MC2 Therapeutics, Allena Pharmaceuticals, Regulus Therapeutics, UnicoCell Biomed, Regeneron Pharmaceuticals and others.
• Promising Chronic Kidney Disease Pipeline Therapies such as roxadustat, Monofer®, AZD5718, Dapagliflozin 10 mg, MEDI8367, AST-120, and others.

Stay informed about the cutting-edge advancements in Chronic Kidney Disease treatments @ Chronic Kidney Disease Clinical Trials Assessment

Chronic Kidney Disease Overview

Chronic Kidney Disease is a condition in which kidneys are damaged and cannot filter blood. As a result, extra fluid and waste from the blood remain in the body, potentially leading to various health issues like heart disease and stroke. Chronic Kidney Disease has various levels of seriousness. It usually gets worse with time though treatment has been shown to slow progression. If left untreated, CKD can progress to kidney failure and early cardiovascular disease. Chronic kidney disease (CKD) often has no symptoms in its early stages, as the kidneys have a significant capacity to compensate for damage. However, as CKD progresses, symptoms may start to appear, including swelling or edema, chest pain, dry skin, itching or numbness, fatigue, headaches, changes in urination patterns, loss of appetite, muscle cramps, nausea, shortness of breath, sleep problems, trouble concentrating, vomiting, and weight loss. People with advanced CKD can also develop complications like anemia, bone disease, and malnutrition.

Chronic Kidney Disease Emerging Drugs Profile

• Ziltivekimab: Novo Nordisk

Ziltivekimab is a proprietary anti-interleukin-6 ligand monoclonal antibody (anti-IL6 mAb), targeting residual inflammatory cardiovascular risk in patients living with advanced chronic kidney disease (CKD). Ziltivekimab is being developed a therapy intended to reduce the risk of major cardiovascular adverse events in chronic kidney disease (CKD) patients with atherosclerotic cardiovascular disease (ASCVD) and inflammation. Patients who are diagnosed with moderate to severe CKD and have ASCVD and inflammation are at risk for an adverse cardiovascular event at a high rate and there are no approved therapies to prevent this risk. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Chronic Kidney Disease.

• Clazakizumab: CSL Behring

Clazakizumab is an investigational humanized monoclonal antibody designed to inhibit interleukin-6 (IL-6), a cytokine involved in inflammation and immune responses. By binding directly to IL-6, clazakizumab prevents its interaction with the IL-6 receptor, thereby modulating downstream inflammatory pathways. According to the company’s pipeline, the drug is being evaluated in a Phase III clinical trial for the treatment of patients with chronic kidney disease.

• AP306: R1 Therapeutics/ Alebund Therapeutics

AP306 is a first-in-class pan phosphate transporter inhibitor being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) undergoing dialysis. The drug works by blocking the active transport of phosphate in the gastrointestinal tract through inhibition of three key phosphate transporters — NaPi-IIb, PiT-1, and PiT-2 — representing a novel mechanism distinct from traditional phosphate binders. Unlike currently available therapies that mainly bind dietary phosphate, AP306 directly inhibits phosphate absorption and has the potential to provide rapid and effective phosphate lowering with a significantly reduced pill burden. Originally discovered by Chugai Pharmaceutical and later licensed to Alebund Pharmaceuticals, the drug was subsequently acquired by R1 Therapeutics through its acquisition of Alebund Pharmaceuticals, giving R1 Therapeutics rights to continue the development of AP306. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Chronic Kidney Disease.

• MZE829: Maze Therapeutics

MZE829 is an investigational oral small-molecule therapy being developed for the treatment of APOL1 kidney disease, a genetically driven form of chronic kidney disease (CKD). The drug is designed as a selective inhibitor of APOL1, a protein associated with kidney injury and progressive renal dysfunction in individuals carrying certain APOL1 genetic variants. MZE829 works by directly inhibiting the toxic activity of APOL1 risk variants, thereby aiming to protect podocytes and reduce kidney damage, inflammation, and proteinuria. The therapy has the potential to address the underlying cause of APOL1-mediated kidney disease rather than only treating symptoms. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Chronic Kidney Disease.

• PXL770: Poxel SA

PXL770 is an investigational oral direct activator of AMP-activated protein kinase (AMPK) being developed for metabolic and kidney-related disorders, including chronic kidney disease (CKD). PXL770 is designed to activate AMPK, a key regulator of cellular energy homeostasis, glucose metabolism, lipid metabolism, inflammation, and fibrosis. By directly activating AMPK, the drug aims to improve mitochondrial function, reduce lipid accumulation, suppress inflammatory and fibrotic pathways, and protect kidney function. PXL770 demonstrated beneficial effects on renal, metabolic, and inflammatory biomarkers in preclinical and clinical studies, supporting its potential as a disease-modifying therapy. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of Chronic Kidney Disease.

• RN-032: Rege Nephro Co., Ltd.

RN-032 is an investigational cell therapy being developed for the treatment of chronic kidney disease (CKD). The therapy uses nephron progenitor cells (NPCs) derived from allogeneic human induced pluripotent stem cells (iPSCs), also referred to as iNPCs. NPCs are precursor cells that give rise to nephrons, the functional units of the kidney. RN-032 is designed to regenerate and repair damaged kidney tissue by implanting these iPSC-derived nephron progenitor cells into injured kidneys. Currently, the drug is being evaluated in the Preclinical stage of its development for the treatment of Chronic Kidney Disease.

The Chronic Kidney Disease Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Kidney Disease with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Kidney Disease Treatment.
• Chronic Kidney Disease Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Chronic Kidney Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Kidney Disease market

Learn more about Chronic Kidney Disease Drugs opportunities in our groundbreaking Research and development projects @ Chronic Kidney Disease Unmet Needs

Chronic Kidney Disease Companies

AstraZeneca, Eli Lilly and Company, Shandong Suncadia Medicine, Boehringer Ingelheim, AdAlta, Alebund Pharmaceuticals, SCOHIA PHARMA, DiaMedica Therapeutics, Roche, MC2 Therapeutics, Allena Pharmaceuticals, Regulus Therapeutics, UnicoCell Biomed, Regeneron Pharmaceuticals and others.

Chronic Kidney Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Chronic Kidney Disease Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Discover the latest advancements in Chronic Kidney Disease treatment by visiting our website @ Chronic Kidney Disease Market Drivers and Barriers, and Future Perspectives

Scope of the Chronic Kidney Disease Pipeline Report

• Coverage- Global
• Chronic Kidney Disease Companies- AstraZeneca, Eli Lilly and Company, Shandong Suncadia Medicine, Boehringer Ingelheim, AdAlta, Alebund Pharmaceuticals, SCOHIA PHARMA, DiaMedica Therapeutics, Roche, MC2 Therapeutics, Allena Pharmaceuticals, Regulus Therapeutics, UnicoCell Biomed, Regeneron Pharmaceuticals and others.
• Chronic Kidney Disease Pipeline Therapies- Roxadustat, Monofer®, AZD5718, Dapagliflozin 10 mg, MEDI8367, AST-120, and others.
• Chronic Kidney Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Chronic Kidney Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Read the full details of Chronic Kidney Disease Pipeline on our website @ Chronic Kidney Disease Emerging Drugs and Companies

Table of Content

1. Introduction
2. Executive Summary
3. Chronic Kidney Disease: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Chronic Kidney Disease– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Ziltivekimab: Novo Nordisk
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. AP306: R1 Therapeutics/ Alebund Therapeutics
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. PXL770: Poxel SA
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. RN-032: Rege Nephro Co., Ltd.
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Chronic Kidney Disease Key Companies
21. Chronic Kidney Disease Key Products
22. Chronic Kidney Disease- Unmet Needs
23. Chronic Kidney Disease- Market Drivers and Barriers
24. Chronic Kidney Disease- Future Perspectives and Conclusion
25. Chronic Kidney Disease Analyst Views
26. Chronic Kidney Disease Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/